London · Delayed Price · Currency is GBP · Price in USD Enovis Company Description
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally.
It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company’s Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.
Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools.
It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.
It distributes its products through independent distributors and directly under the ESAB and DJO brands.
The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1995 |
| Industry | Industrial - Capital Goods |
| Sector | Industrials |
| Employees | 7,367 |
| CEO | Damien McDonald |
Contact Details
Address: 2711 Centerville Road Wilmington, Delaware 19808 United States | |
| Phone | 302 252 9160 |
| Website | enovis.com |
Stock Details
| Ticker Symbol | 0I1B |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US1940145022 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Damien McDonald | Chief Executive Officer |
| Phillip Berry | Chief Financial Officer |
| Kyle Rose | Head of Investor Relations |